AstraZeneca Combo for Type 2 Diabetes Gets Green Light in EUAstraZeneca Combo for Type 2 Diabetes Gets Green Light in EU
The EMA has given the green light to a fixed-dose combination of saxagliptin and dapagliflozin, the first combination of DPP-4/SGLT2 inhibitor in Europe, for the treatment of type 2 diabetes. International Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news
More News: AstraZeneca | Dapagliflozin | Diabetes | Diabetes Type 2 | Endocrinology | Forxiga | SGLT2 Inhibitors